Regeneron Announces Presentation at the Cowen and Company 30th Annual Healthcare Conference
TARRYTOWN, N.Y., March 4 Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the Cowen and Company 30th Annual Healthcare Conference on Tuesday, March 9, 2010. The presentation is scheduled for 11:05 a.m. Eastern Time. The session may be accessed through the Company's web site, www.regeneron.com, on the Investor Relations page. An archived version of the presentation will be available after the live webcast through April 8, 2010. Additional information about Regeneron and recent news releases are available on the Regeneron web site.
Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, age-related macular degeneration, and certain cancers. Additional therapeutic candidates are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic conditions, and cancer. Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com
Contact Information: Peter Dworkin Laura Lindsay Investor Relations Media Relations 914.345.7640 914.345.7800 firstname.lastname@example.org email@example.com
SOURCE Regeneron Pharmaceuticals, Inc.
You May Also Like